With emerging evidence that Sox9 may contribute to maintenance of breast cancer stem cells, the inducible Sox9 deletion model and the insights presented here should facilitate future efforts to validate Sox9 as a biomarker or therapeutic target in breast cancer. This evidence concerns the gene SOX9 and breast cancer.